Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-13 disrupts type 2 pneumocyte stem cell activity
Kristen M. Glisinski, Adam J. Schlobohm, Sarah V. Paramore, Anastasiya Birukova, M. Arthur Moseley, Matthew W. Foster, Christina E. Barkauskas
Kristen M. Glisinski, Adam J. Schlobohm, Sarah V. Paramore, Anastasiya Birukova, M. Arthur Moseley, Matthew W. Foster, Christina E. Barkauskas
View: Text | PDF
Research Article Pulmonology Stem cells

Interleukin-13 disrupts type 2 pneumocyte stem cell activity

  • Text
  • PDF
Abstract

The T helper 2 (Th2) inflammatory cytokine interleukin-13 (IL-13) has been associated with both obstructive and fibrotic lung diseases; however, its specific effect on the epithelial stem cells in the gas exchange compartment of the lung (alveolar space) has not been explored. Here, we used in vivo lung models of homeostasis and repair, ex vivo organoid platforms, and potentially novel quantitative proteomic techniques to show that IL-13 disrupts the self-renewal and differentiation of both murine and human type 2 alveolar epithelial cells (AEC2s). Significantly, we find that IL-13 promotes ectopic expression of markers typically associated with bronchiolar airway cells and commonly seen in the alveolar region of lung tissue from patients with idiopathic pulmonary fibrosis. Furthermore, we identify a number of proteins that are differentially secreted by AEC2s in response to IL-13 and may provide biomarkers to identify subsets of patients with pulmonary disease driven by “Th2-high” biology.

Authors

Kristen M. Glisinski, Adam J. Schlobohm, Sarah V. Paramore, Anastasiya Birukova, M. Arthur Moseley, Matthew W. Foster, Christina E. Barkauskas

×

Figure 3

IL-13 disrupts AEC2 differentiation in vitro.

Options: View larger image (or click on image) Download as PowerPoint
IL-13 disrupts AEC2 differentiation in vitro.
(A) Control organoids expr...
(A) Control organoids express both AEC2 (DC-LAMP) and AEC1 (HOPX, PDPN) markers. The morphology of most IL-13–treated spheres is abnormal, with only a single layer of epithelial cells. There are AEC2 and AEC1 markers present, but these occur in an apparently random distribution not seen in control spheres. (B) Compared with control organoids, IL-13–treated organoids contain a higher proportion of cells that lack both AEC2 and AEC1 markers. One-way ANOVA; error bars indicate mean ± SD. **P < 0.005. (C) RNA-Seq of day 16 organoids grown in the presence of IL-13 (compared with control conditions) reveals increased expression of bronchiolar markers (n = 3 biological replicates per condition; asterisk indicates genes significantly differentially expressed). (D) Lineage-labeled (Tomato+) organoids grown in the presence of IL-13 express more SOX9 and display more proliferation (MKI67) than lineage-labeled organoids grown in control conditions. (E) IL-13 induces ectopic expression of KRT5 in AEC2s. An AEC2-derived sphere (arrow) grown in control conditions expresses AEC2 (DC-LAMP) and AEC1 (PDPN) markers but not KRT5. A rare contaminating basal cell–derived organoid (asterisk) serves as a positive control, demonstrating expected KRT5 staining. In contrast, a proportion of IL-13–treated spheres express KRT5. (F) KRT5 expression in IL-13–treated spheres is supported with use of a Krt5GFP reporter mouse line. Scale bars: 50 μm (A); 50 μm, insets 25 μm (D); 75 μm (E); and 50 μm (F).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts